Imprimis’ Q2-2017 Ophthalmology Revenues Increase 70 percent

August 11, 2017: By Jon Swedien

ImprimisImprimis Pharmaceuticals’ gross revenues related to ophthalmology totaled $4.7 million in Q2-2017, a 70 percent increase over Q2-2016, the San Diego-based company reported Aug. 10.

The company’s total revenues for Q2-2017 were $6.9 million, a 40 percent increase compared with Q2-2016, said Imprimis, a pharmaceutical company focused on increasing patient access and affordability to critical medicines.

Imprimis had a net income of $1.5 million, or $0.07 per share of common stock (basic). CEO Mark Baum said it was the company’s first quarter of recorded net income.

The company also noted that it achieved the milestone of its products being used in 1 million patient eyes since the launch of its ophthalmic portfolio in April 2014.

And Imprimis announced that it created a new wholly owned subsidiary, Surface Pharmaceuticals, Inc., which will focus on ocular surface disease treatments that are expected to be developed as branded drugs through the FDA’s 505(b)(2) development pathway.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Launches Stellaris Elite for Retinal Surgery in US

Sentencing Delayed for Florida Retina Specialist Melgen

Valeant Receives FDA Complete Response Letter for Vyzulta

US FDA Clears Optovue Software for Corneal Epithelial Thickness Mapping

Ocular Therapeutix Names Daniel Bollag as Regulatory Chief

Eylea Sales Continue to Increase; Lucentis Gains New Indications

RXi Pharmaceuticals Signs Common Stock Purchase Agreement for Up to $15 Million

Allegro’s Luminate Posts Positive Results in Phase IIb Stage 2 Trial for Diabetic Macular Edema

Omeros’ Omidria Revenues Grow 71 Percent

AGTC Receives US FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa

Aerpio Shares Begin Trading on OTCQB Market

Aerie Reports FDA Concerns over Contract Manufacturer’s Plant

Valeant’s Bausch + Lomb Revenues Dip 3 percent in Q2-2017

Ocular Therapeutix Reports $66 Million in Cash, Cash Equivalents

Imprimis’ Q2-2017 Ophthalmology Revenues Increase 70 percent

Carl Zeiss Meditec’s Revenues Grow 7.5 Percent in Latest Quarter

Johnson & Johnson Vision to Acquire TearScience

Mynosys Receives $1 Million Grant from NEI to Commercialize Zepto

Ocular Therapeutix Eliminates 26 Positions; New CEO Takes Helm

Inotek Stops Development of Trabodenoson after Second Failed Study

Coming soon

2017 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2016 to 2022